VS-105

VS-105 has been studied in 1 paper since 2020: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Nov 6, 2020: “A Novel Vitamin D Receptor Agonist, VS-105, Improves Bone Mineral Density without Affecting Serum Calcium in a Postmenopausal Osteoporosis Rat Model”.

Intervention

1 paper studies it3 findingsUpdated

PubChem

See all 1 papers on VS-105

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

None of its findings points the other way.

Cells and mice: a single group. Worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • Funders: National Institute of Arthritis and Musculoskeletal and Skin Diseases and 1 more
  • 3 of 3 findings with company ties
  • Animals1

What did studies of VS-105 find?

3

Studies of VS-105 measured 3 outcomes: net calcium release, serum calcium and lumbar vertebral bone mineral density.

Net calcium release

downin rat cells1

1 study
  1. VS-105 decreases net calcium release in rat cells (organ culture; compared with calcitriol).

    “In the calvariae bone organ culture, net Ca release was significantly less in VS-105-treated groups (vs. calcitriol).”

    Cellsorgan culture; compared with calcitriolcalvarial bone

    A Novel Vitamin D Receptor Agonist, VS-105, Improves Bone Mineral Density without Affecting Serum Calcium in a Postmenopausal Osteoporosis Rat Model

    Journal of exploratory research in pharmacology

More on Net calcium release

Serum calcium

no changein rats1

1 study
  1. VS-105 showed no clear effect on serum calcium in rats (ovariectomized osteoporosis rat model).

    “VS-105 is efficacious in improving BMD in a dose range that does not affect serum Ca in OVX rats”

    Animalsovariectomized osteoporosis rat model0.1, 0.2 or 0.5 μg/kg, 3×/week90 days

    A Novel Vitamin D Receptor Agonist, VS-105, Improves Bone Mineral Density without Affecting Serum Calcium in a Postmenopausal Osteoporosis Rat Model

    Journal of exploratory research in pharmacology

More on Serum calcium

Lumbar vertebral bone mineral density

upin rats1

1 study
  1. VS-105 increases lumbar vertebral bone mineral density in rats (ovariectomized osteoporosis rat model) (OVX/vehicle: 279 ± 10 mg/cm2; VS-105 at 0.1, 0.2 and 0.5 μg/kg: 306 ± 9, 329 ± 12, and 327 ± 10 mg/cm2).

    “significantly improved BMD in the L3 lumbar vertebra in a dose-dependent manner”

    Animalsovariectomized osteoporosis rat modelL3 lumbar vertebra0.1, 0.2 or 0.5 μg/kg, 3×/week90 days

    A Novel Vitamin D Receptor Agonist, VS-105, Improves Bone Mineral Density without Affecting Serum Calcium in a Postmenopausal Osteoporosis Rat Model

    Journal of exploratory research in pharmacology

Latest